These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. Condino-Neto A; Costa-Carvalho BT; Grumach AS; King A; Bezrodnik L; Oleastro M; Leiva L; Porras O; Espinosa-Rosales FJ; Franco JL; Sorensen RU Allergol Immunopathol (Madr); 2014; 42(3):245-60. PubMed ID: 23333411 [TBL] [Abstract][Full Text] [Related]
17. Osmotic demyelination syndrome: variable clinical and radiologic response to intravenous immunoglobulin therapy. Murthy SB; Izadyar S; Dhamne M; Kass JS; Goldsmith CE Neurol Sci; 2013 Apr; 34(4):581-4. PubMed ID: 22491911 [No Abstract] [Full Text] [Related]
18. Relevance of quantitative measurements of anti-Abeta antibodies in therapeutic intravenous immunoglobulin using synthetic peptides. Jorquera JI Int Immunopharmacol; 2010 Mar; 10(3):373-4; author reply 375-6. PubMed ID: 20018258 [No Abstract] [Full Text] [Related]
19. High cost of immunoglobulin replacement therapy: Causes and implications. Sun D; Romberg N Ann Allergy Asthma Immunol; 2022 Nov; 129(5):645. PubMed ID: 36333061 [No Abstract] [Full Text] [Related]
20. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]